{"entity":{"id":"idea-rejuv-second-cancer-latency-cohort-for-new-drugs","kind":"idea","name":"Enrol every new systemic therapy into a registry linkage that will still report in thirty years","aka":[],"tldr":"A second cancer after radiotherapy can take forty years to appear. Checkpoint inhibitors and antibody-drug conjugates have been in first-line use for a few, so nobody can say anything about their late effects, and nobody is building the thing that could.","summary":"The honest position on the late effects of modern treatment is that they are unmeasurable, not that they are absent. Follow-up of commercial CAR-T cohorts is short relative to the latency of second cancers; the FDA's 2024 labelling action on secondary T-cell malignancy states no incidence; whether the immunotherapies and antibody-drug conjugates now in first-line use carry such a risk is not yet measurable. The same applies in the reassuring direction: whether smaller modern radiotherapy fields lowered the forty-year second cancer rate is not known because nobody has been followed that long.\n\nWaiting will not fix this, because the follow-up mechanism does not exist. Trial follow-up ends when the registration endpoint is met; extension studies are voluntary and lose people; pharmacovigilance describes reporting, not incidence. The paediatric cohorts show what works: abstract exposures at entry, link to registries, and the answer arrives decades later without anyone having to remember.\n\nThe proposal is to make that routine. At the point of approval, every new systemic cancer therapy enters a national registry linkage keyed to the treatment record, with second cancers, cardiovascular events and mortality reported from routine data rather than from sponsor follow-up. The marginal cost is in the linkage and the consent architecture, and it is the same infrastructure a late-effects registry needs, which is why the two proposals belong together.","asOf":"2026-10-02","links":[{"label":"Schaapveld et al., Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma (NEJM 2015)","url":"https://doi.org/10.1056/NEJMoa1505949"}],"tags":["rejuvenation","survivorship","open-problem","second-cancers","latency"],"related":["rejuv-tx-secondary-t-cell-malignancy","rejuv-tx-gene-modified-follow-up","rejuv-second-platinum-and-parp-inhibitors","idea-acc-national-late-effects-registry","idea-moon-adult-late-effects-registry","rejuvenation-roadmap"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["rejuv-agenda-latency-outruns-the-evidence","rejuv-agenda-late-effects-are-not-counted","b-real-world-evidence","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A registry linkage established at approval and running on routine data will produce measurable late-effect rates for modern therapies within fifteen to twenty-five years, which no current mechanism will.","rationale":"The latency of solid second cancers after treatment exceeds the follow-up of every modern drug programme. Gene-modified cell therapy already carries a fifteen-year long-term follow-up recommendation, and the transplant facet records its honest limit: no randomised evidence exists, or could exist, that following an individual for fifteen years improves their outcome, and loss to follow-up is the known failure mode. A passive registry linkage does not depend on the individual staying in contact.","test":"Pilot in a country with linked national cancer registry, prescribing and hospital data: enrol one modern drug class at approval, demonstrate that second cancers and cardiovascular events can be reported from routine data at five years, and compare completeness against the sponsor's own extension study.","maturity":"speculative","actor":"regulator","cost":"medium","horizonYears":15},"route":"/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/","neighbours":{"technology":[{"id":"rejuv-tx-gene-modified-follow-up","kind":"technology","name":"Long-term follow-up for gene-modified cell products: fifteen years, and why","route":"/technologies/rejuv-tx-gene-modified-follow-up/"},{"id":"rejuv-tx-secondary-t-cell-malignancy","kind":"technology","name":"Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says","route":"/technologies/rejuv-tx-secondary-t-cell-malignancy/"}],"term":[{"id":"rejuv-second-platinum-and-parp-inhibitors","kind":"term","name":"Platinum drugs and PARP inhibitors: the newer leukaemia risk","route":"/terms/rejuv-second-platinum-and-parp-inhibitors/"}],"idea":[{"id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/"},{"id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/"}],"roadmap":[{"id":"rejuvenation-roadmap","kind":"roadmap","name":"Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it","route":"/roadmaps/rejuvenation-roadmap/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"bottleneck":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"rejuv-agenda-late-effects-are-not-counted","kind":"bottleneck","name":"Registries count diagnoses and deaths, and not what treatment left behind","route":"/bottlenecks/rejuv-agenda-late-effects-are-not-counted/"},{"id":"rejuv-agenda-latency-outruns-the-evidence","kind":"bottleneck","name":"The newest treatments have not existed long enough for their late effects to appear","route":"/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}]}}